RE:AEZS Q4 "Dr. Klaus Paulini, Chief Executive Officer of Aeterna commented, “With enrollment now completed in the DETECT-trial, we expect the completion of the DETECT-trial in the second quarter and Top-Line Data in the third quarter of this year." news release
That sets up a potential North American diagnostic deal. Strongbridge's upfront payment, adjusted for inflation, was ~C$40 million and that was without a pediatric clinical trial completed. It was also to provide US$5 million on pediatric approval and to help cover the pediatric test trial. AEZS can now conceivably receive the US$5 million pediatric approval milestone and trial costs in the form of an upfront payment. AEZS is also pursuing deals outside North America and could receive pediatric milestones from current European deals, etc.
AEZS's existing cash according to its financial statements:
"We also believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements beyond the next 12 months and through 2025."
Conceivably that could be complemented by cash from a new diagnostic deal(s).